REGENXBIO Q2 net income $22.7M; RGX-202 BLA on track; cash runway to Q4 2027

REGENXBIO Inc.

Net income of $22.7M ($0.43 per share) vs net loss of $70.9M in Q2 2025; revenue $108.0M (incl. $100M AbbVie milestone).
RGX-202 Phase III AFFINITY DUCHENNE trial met primary endpoint (p<0.0001); BLA submission on track for Q3 2026 with potential accelerated approval 2H 2027.
RGX-121 BLA resubmission on track for Q3 2026 after positive FDA Type A meeting; no additional studies required.
Sura-vec (ABBV-RGX-314) pivotal wet AMD data expected Q4 2026; first patient dosed in NAAVIGATE DR study triggered $100M milestone.
Pro forma cash ~$313M after July 2026 milestone and public offering; cash runway extended into Q4 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.